vs

Side-by-side financial comparison of Journey Medical Corp (DERM) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $9.6M, roughly 1.7× Red Cat Holdings, Inc.). Journey Medical Corp runs the higher net margin — -7.8% vs -166.0%, a 158.3% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 27.3%).

Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

DERM vs RCAT — Head-to-Head

Bigger by revenue
DERM
DERM
1.7× larger
DERM
$16.1M
$9.6M
RCAT
Growing faster (revenue YoY)
RCAT
RCAT
+960.9% gap
RCAT
988.2%
27.3%
DERM
Higher net margin
DERM
DERM
158.3% more per $
DERM
-7.8%
-166.0%
RCAT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DERM
DERM
RCAT
RCAT
Revenue
$16.1M
$9.6M
Net Profit
$-1.2M
$-16.0M
Gross Margin
6.6%
Operating Margin
-2.8%
-181.7%
Net Margin
-7.8%
-166.0%
Revenue YoY
27.3%
988.2%
Net Profit YoY
-182.0%
-29.0%
EPS (diluted)
$-0.04
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DERM
DERM
RCAT
RCAT
Q4 25
$16.1M
Q3 25
$17.0M
$9.6M
Q2 25
$15.0M
Q1 25
$13.1M
$1.6M
Q4 24
$12.6M
$0
Q3 24
$14.6M
Q2 24
$14.9M
Q1 24
$13.0M
$5.8M
Net Profit
DERM
DERM
RCAT
RCAT
Q4 25
$-1.2M
Q3 25
$-2.3M
$-16.0M
Q2 25
$-3.8M
Q1 25
$-4.1M
$-23.1M
Q4 24
$1.5M
$-13.3M
Q3 24
$-2.4M
Q2 24
$-3.4M
Q1 24
$-10.4M
$-5.5M
Gross Margin
DERM
DERM
RCAT
RCAT
Q4 25
Q3 25
6.6%
Q2 25
Q1 25
-52.2%
Q4 24
82.3%
Q3 24
63.9%
Q2 24
56.0%
Q1 24
47.7%
18.8%
Operating Margin
DERM
DERM
RCAT
RCAT
Q4 25
-2.8%
Q3 25
-9.0%
-181.7%
Q2 25
-19.2%
Q1 25
-25.3%
-765.7%
Q4 24
17.7%
Q3 24
-19.8%
Q2 24
-19.7%
Q1 24
-77.4%
-76.0%
Net Margin
DERM
DERM
RCAT
RCAT
Q4 25
-7.8%
Q3 25
-13.6%
-166.0%
Q2 25
-25.3%
Q1 25
-31.0%
-1418.9%
Q4 24
12.1%
Q3 24
-16.3%
Q2 24
-22.6%
Q1 24
-80.1%
-93.9%
EPS (diluted)
DERM
DERM
RCAT
RCAT
Q4 25
$-0.04
Q3 25
$-0.09
$-0.16
Q2 25
$-0.16
Q1 25
$-0.18
$-0.27
Q4 24
$0.10
Q3 24
$-0.12
Q2 24
$-0.17
Q1 24
$-0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DERM
DERM
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$24.1M
Total DebtLower is stronger
$25.3M
Stockholders' EquityBook value
$31.9M
$253.3M
Total Assets
$94.6M
$286.0M
Debt / EquityLower = less leverage
0.79×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DERM
DERM
RCAT
RCAT
Q4 25
$24.1M
Q3 25
$24.9M
Q2 25
$20.3M
Q1 25
$21.1M
Q4 24
$20.3M
Q3 24
$22.5M
Q2 24
$23.9M
Q1 24
$24.1M
Total Debt
DERM
DERM
RCAT
RCAT
Q4 25
$25.3M
Q3 25
$25.2M
Q2 25
$25.1M
Q1 25
$25.0M
Q4 24
$24.9M
Q3 24
$19.8M
Q2 24
$19.7M
Q1 24
$14.7M
Stockholders' Equity
DERM
DERM
RCAT
RCAT
Q4 25
$31.9M
Q3 25
$25.9M
$253.3M
Q2 25
$19.2M
Q1 25
$21.5M
$28.9M
Q4 24
$20.1M
$27.0M
Q3 24
$10.9M
Q2 24
$11.3M
Q1 24
$13.0M
$49.6M
Total Assets
DERM
DERM
RCAT
RCAT
Q4 25
$94.6M
Q3 25
$85.2M
$286.0M
Q2 25
$81.2M
Q1 25
$85.0M
$59.7M
Q4 24
$80.2M
$51.1M
Q3 24
$64.0M
Q2 24
$65.2M
Q1 24
$66.6M
$55.3M
Debt / Equity
DERM
DERM
RCAT
RCAT
Q4 25
0.79×
Q3 25
0.97×
Q2 25
1.30×
Q1 25
1.16×
Q4 24
1.24×
Q3 24
1.81×
Q2 24
1.75×
Q1 24
1.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DERM
DERM
RCAT
RCAT
Operating Cash FlowLast quarter
$-6.3M
$-23.9M
Free Cash FlowOCF − Capex
$-24.5M
FCF MarginFCF / Revenue
-254.2%
Capex IntensityCapex / Revenue
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DERM
DERM
RCAT
RCAT
Q4 25
$-6.3M
Q3 25
$-2.4M
$-23.9M
Q2 25
$-942.0K
Q1 25
$-2.8M
$-15.9M
Q4 24
$2.2M
$-10.1M
Q3 24
$-1.2M
Q2 24
$-5.2M
Q1 24
$-5.0M
$-4.1M
Free Cash Flow
DERM
DERM
RCAT
RCAT
Q4 25
Q3 25
$-24.5M
Q2 25
Q1 25
$-16.2M
Q4 24
$-10.2M
Q3 24
Q2 24
Q1 24
$-4.2M
FCF Margin
DERM
DERM
RCAT
RCAT
Q4 25
Q3 25
-254.2%
Q2 25
Q1 25
-992.9%
Q4 24
Q3 24
Q2 24
Q1 24
-71.1%
Capex Intensity
DERM
DERM
RCAT
RCAT
Q4 25
Q3 25
6.9%
Q2 25
Q1 25
16.8%
Q4 24
Q3 24
Q2 24
Q1 24
0.8%
Cash Conversion
DERM
DERM
RCAT
RCAT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.46×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DERM
DERM

Qbrexza$5.5M35%
Emrosi$5.0M31%
Accutane$3.1M19%
Other$2.5M15%

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons